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Background: One of the greatest challenges in cardiovascular medicine is to define the best tools for performing
an accurate risk stratification for the recurrence of ischemic events in acute coronary syndrome (ACS) patients.
Methods: We followed 65 ACS patients enrolled in a previous pilot study for 2 years after being discharged,
focusing on the occurrence of major adverse cardiovascular events (MACE).
The relationship between serum tryptase levels on admission, SYNergy between percutaneous coronary
intervention with the TAXUS drug-eluting stent and the cardiac surgery score (SX-score), cardiovascular complexity
and MACE at 2 years follow-up were analyzed.
Results: The ACS population was divided in two groups: patients with MACE (n = 23) and patients without
MACE (n = 42).
The tryptase measurement at admission (T0) and at discharge (T3) and SX-score were higher in patients who
experienced MACE than in those without (p = 0.0001, p < 0.0001 and p = 0.006, respectively). Conversely, we found
no significant association between MACE and C-reactive protein (CRP), and between MACE and maximum level of
high-sensitivity troponin (hs-Tn) values.
Among all patients with MACE, 96% belonged to the group that presented with cardiovascular complexity at the
beginning of ACS index admission (p < 0.0001).
The predictive accuracy of serum tryptase for MACE at follow up set at the cut-off point of 4.95 ng/ml at T0 and of
5.2 ng/ml at T3. Interestingly, patients with both the above cut-off tryptase values at T0 and at T3 presented a
1320% increase in the odds of developing MACE (p < 0.0001).
Conclusion: In ACS patients, serum tryptase measured during index admission is significantly correlated to the
development of MACE up to 2 years, demonstrating a possible long-term prognostic role of this biomarker.
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Major adverse cardiovascular events, such as myocardial
infarction, cardiac arrhythmia, target vessel failure, heart
failure, and death from all causes, are severe and feared
sequelae of patients who develop ACS. Thus, one of the
greatest challenges in cardiovascular medicine is to find
a way to predict the risk of short- and long-term MACE
in ACS patients.
During the last few decades, several proteins have been
investigated as potential diagnostic and prognostic bio-
markers in ACS patients. Indeed, atherosclerosis and
plaque destabilization are due to a heterogeneous process
involving vascular inflammation, endothelial dysfunction,
and hypercoagulability. Some blood biomarkers may re-
flect the severity of these pathological processes associated
with the progression of atheromatous lesion [1] and con-
sequently predict the occurrence of MACE [2]. However,
studies evaluating the prognostic role of several relevant
biomarkers have not yet given conclusive and convincing
results. Hs-Tn has shown an excellent negative prognostic
value for predicting long-term MACE. Furthermore,
hs-Tn is the reference standard for early diagnosis of
myocardial infarction. However, to achieve the best clinical
use, hs-Tn has to be used in conjunction with clinical
judgment and ECG.
Indeed, hs-Tn increase may be an expression of plaque
rupture, atherosclerosis or discrepancy between elevated
oxygen demand and supply. Patients with plaque rupture
do certainly profit from more aggressive antiplatelet
therapy, whereas patients with atherosclerosis should be
treated with a more conservative approach. Hs-Tn may
also detect myocardial injury even without an ongoing
ACS [3-5]. Therefore, to increase the performance of
this biomarker for the diagnostic and prognostic pur-
poses, we have to carefully consider the prevalence of
disease within a given population and patient comorbi-
dities. All these considerations warrant cardiovascular
research to find a new and more meaningful biomarker.
Evidence that chronic inflammatory states can aggravate
atherogenesis are accumulating. Consequently, inflam-
matory biomarkers could be a great resource by helping
to clarify the pathophysiological mechanisms linking in-
flammation to cardiovascular disease, to improve the
prognostic value of existing tools, and to identify novel
therapeutic targets. In this light, Pastorello et al. have re-
cently evaluated the role of tryptase as a prognostic
marker of cardiovascular complexity in ACS [6]. The re-
sults showed an association among this inflammatory
biomarker and the angiographic extension of cardiovas-
cular disease, as defined by the SX-score.
Tryptase is a mast cell serine protease mediator im-
plicated in many different inflammatory processes. This
protein might be involved in atherosclerotic plaque pro-
gression and destabilization in the ACS setting, and itcould, thus, be a valid expression of the bulk of vascular
involvement [7]. Therefore, tryptase could be a predictive
marker of recurrent adverse events in ACS patients. The
aims of this study were to evaluate the development of
MACEs within 2 years after an initial coronary angio-
graphy in ACS patients and to define the relationship
between serum tryptase levels, SX-score, and cardiovas-
cular complexity reported during acute events, in order to
understand the predictive role of serum tryptase levels.
Methods
Study population
A sample of 65 patients, consecutively admitted to the
Cardiology Department from April 2012 to September
2012, who underwent coronary angiography for ACS
was included in a previous study to evaluate the corre-
lation between clinical data and tryptase levels. All the
patients with a history of concomitant mastocytosis and
severe allergic diseases were formally excluded. Further-
more, in the selected patients a clinical evaluation for auto-
immunity, cancer, renal failure, myelodysplastic syndromes
and hypereosinophilic syndrome or other hematological
disorders was performed. The study subjects gave informed
consent. These patients were evaluated for cardiovascular
complexities based on the presence of at least two of the
following clinical adverse events at hospitalization: at least
two epicardial coronary arteries involved in the athe-
rosclerotic disease, more than 1 stent implanted, or more
than 2 coronary artery disease risk factors. In the cohort of
65 patients previously described, we performed a follow-up
evaluation beginning at post-discharge and lasting 2 years.
This study was approved by the Ethical Committee of
Niguarda Ca’ Granda Hospital (Protocol Registration
System. ClinicalTrials.gov. Number:193_05/2012).
Clinical follow-up
All the patients were assessed with regular controls and the
follow-up data, focusing on the occurrence of MACE. Data
were obtained from outpatient visits and medical records.
MACE was defined as recurrent myocardial infarction,
unplanned percutaneous coronary intervention (PCI),
cardiac arrhythmias, systemic embolism, heart failure, and
death from all causes. Myocardial infarction was defined as
the clinical diagnosis of ST-elevation myocardial infarction
(STEMI) and non-ST elevation myocardial infarction
(NSTEMI) in accordance with current guidelines of the
European Society of Cardiology [8]. Unplanned coronary
revascularization was defined as unplanned repeated PCI
or coronary bypass grafting. Cardiac arrhythmia was
defined as any cardiac arrhythmia leading to prolonged
hospitalization. Systemic embolism was defined as abrupt
vascular insufficiency associated with clinical or radiological
evidence of arterial occlusion in the absence of other likely
mechanisms. Heart failure was defined as radiographic
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demonstrating pulmonary rales greater than basilar, the
development of a new S3 gallop and the requirement for
inotropic support or intravenous diuretic therapy for left-
ventricular dysfunction. Death was defined as any cardio-
vascular and non-cardiovascular death occurring during
the follow-up period.
Biomarker evaluations
Details about the serum values of tryptase, cardiac
troponin, and CRP measurement and their analyses
were reported in a previous study [6]. Serum tryptase
levels were measured at T0 and at T3 when all the
symptoms and signs of the acute presentation were
resolved. The quantitative measurement of tryptase
was performed using an ImmunoCAP tryptase in
vitro fluoro-enzyme-immunoassay test (Phadia, now
Thermo Fisher Scientific, Uppsala, Sweden), according
to the manufacturer’s instruction. This laboratory
method measures the total tryptase levels of all pro-
forms of α-tryptase and β-tryptase as well as mature
β-tryptase. A normal tryptase level is considered < 5 ng/ml.
Cardiac troponin levels were the maximum value
obtained, and the CRP levels were those obtained at
admission.
Statistical analysis
Data were analyzed by usual descriptive techniques, cate-
gorical data were tabulated with their relative and absolute
frequencies, and continuous variables were described by
the mean ± standard deviation, or by median and range.
Fisher’s exact test and the McNemar test were used to
check significance of cross-tabulations, for between- and
within-groups analyses.
Univariate and multivariate logistic regression were
used to evaluate the effects of the variables on complica-
tion occurrence, with the Wald test used to check the
significance of each single variable. For significant vari-
ables, a further ROC analysis was carried out to search
for a possible cut-off value, and the corresponding ROC
curve was traced. For these cut-off values, sensitivity,
specificity, positive predictive value (PPV), and negative
predictive value (NPV) were calculated.
Results
The ACS population was divided in two groups: patients
with MACE (n = 23; 35.3%: 15 STEMI and 8 NSTEMI)
and patients without MACE (n = 42; 64.7%: 35 STEMI
and 7 NSTEMI). In particular, among MACE patients,
16/23 have developed recurrent myocardial infarction,
3/23 systemic embolysm and 4/23 heart failure. Stent
thrombosis occurred in 1 out of 16 patients with recur-
rent myocardial infarction. In patients with MACE, the
tryptase values [median tryptase level at T0 7.02 ng/ml(range: 1.49 ng/ml to 31.6 ng/ml) and median tryptase
level at T3 5.70 ng/ml (range: 1.60 ng/ml to 19.6 ng/ml)]
were significantly higher than in those without MACE
[median tryptase level at T0 4.55 ng/ml (range: 1.29 ng/ml
to 13.6 ng/ml); median tryptase level at T3 3.80 ng/ml
(range: 1.16 ng/ml to 11.3 ng/ml)].
Therefore, the association between high tryptase levels
at T0 and T3 and subsequent development of MACE was
statistically significant (Mann–Whitney U test: p < 0.0001)
for the overall cohort. We found that any arbitrary uni-
tary increase (+1 ng/ml) in tryptase values at T0 corre-
sponded to a 38% [95% interval confidence (CI): 8% to
75%; p = 0.010] increase in the odds of developing
MACE after two years from the acute event. At T3, we
found that any arbitrary unitary increase (+1 ng/ml) in
tryptase values corresponded to a 57% (95% CI: 13% to
118%; p = 0.008) increase in the odds of developing
MACE after two years from the acute event.
We also found that, among all MACE patients, 96%
belonged to the group that presented a cardiovascular
complexity at the beginning of ACS index admission
(McNemar test: p < 0.0001). The risk to develop MACE
was also significantly correlated to cardiovascular com-
plexity when adjusted for tryptase value at T0 and T3
(Wald test: p = 0.029, and p = 0.033, respectively). We
searched for a possible cut-off value for tryptase values
at T0 and at T3 as a predictor of MACE using the
Youden method after a ROC analysis. The optimal cut-
off for the tryptase at T0 was 4.85 ng/ml, where predic-
tive positive value (PPV) and negative predictive value
(NPV) were 94.9% (95%% CI 82.7% to 99.5%) and 76.9%
(95% CI 56.4% to 91.0%), respectively, and with 86.0%
sensitivity (95%% CI 72.1% to 94.7%) and 90.9% spe-
cificity (95% CI 70.8% to 98.9%). The optimal cut-off for
the tryptase at T3 was 5.2 ng/ml (Figure 1), where PPV
and NPV were 70.8% (95% CI 48.9% to 87.4%) and
85.4% (95% CI 70.8% to 94.4%), respectively, and with
73.9% sensitivity (95% CI 51.6% to 89.8%) and 83.3%
specificity (95% CI 68.6% to 93.0%). Patients with try-
ptase value ≥ 4.85 ng/ml at T0 had a 700% increase in
the odds of MACE development after 2 years (Wald test:
p = 0.003). Tryptase value ≥ 5.2 ng/ml at T3 was asso-
ciated with a 1300% increase in the odds of MACE de-
velopment after 2 years (Wald test: p < 0.0001). Those
with both the above cut-off tryptase values at T0 and at
T3 presented a 1320% increase in the odds of developing
MACE (Wald test: p < 0.0001).
The boxplots in Figure 2 show the measures of asso-
ciation between MACE, serum tryptase at T3 and SX
score: in both cases, values are significantly higher in those
patients who developed MACE (Mann–Whitney U test:
p < 0.0001 and p = 0.0006, respectively). Conversely, there
was not relevant association between hs-Tn (p = 0.6010),
nor CRP (p = 0.8623) and follow up MACE.
Figure 1 ROC curves reporting AUC calculated at the time of acute event for tryptase, cardiac troponin, CRP, and SX-score, with
respect to MACE: AUC of tryptase and SX-score appear significantly higher than the other AUCs. ROC analysis to search for cut-off values
of the different markers predictive of MACE.
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In the present study, we looked for the development of
MACE at 2 years in a cohort of patients with ACS who
were previously enrolled in a pilot study aimed at estimat-






























Figure 2 Box plot for tryptase at T3, CRP, cardiac troponin measurem
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diovascular complexity and high tryptase levels during
hospitalization. We also found that serum tryptase levels
were significantly related to the severity of the coronary
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ACS, with 3 of them dying from cardiac causes and the
others presenting a new myocardial infarction (n = 18) or
systemic embolism (n = 2).
Therefore, in the present study, we analyzed the correl-
ation between the development of MACE and some
angiographic and clinical parameters, such as SX-score
and cardiovascular complexity, and the previously eva-
luated biological biomarkers, such as serum tryptase,
hs-Tn and CRP. This study demonstrated a correlation
between a high SX-score and the development of MACE
at two years. Patients with MACE demonstrated a mean
SX-score of 16.8, compared to the measure of 9.2 found in
patients without MACE. This result confirms the data in
the literature. In a recent trial of 1,132 ACS patients
undergoing PCI, patients who experienced MACE at
1 year presented high (≥19) or intermediate (11–18) SX-
score [10]. This shows that the SX-score is a useful scoring
system to assess the severity of coronary artery disease
and to determine the appropriate revascularization stra-
tegy [11]. Furthermore, the SX-score is an independent
predictor of MACE in ACS patients [12].
An original result of the present study was that 96% of
MACE patients presented signs of cardiovascular com-
plexity during the cardiac acute event, and only 1 out of 4
ACS complex patients did not develop MACE at 2 years,
with a significant difference in cardiovascular complexity
between patients with MACE and those without.
Thus, the presence of at least two signs of cardiovas-
cular complexity upon admission to a hospital may be
correlated to the recurrence of cardiovascular events.
Another finding was that a significantly higher level of
serum tryptase was evident in patients with MACE
compared to those without (mean tryptase levels of
13.8 ng/ml and 9.1 ng/ml, respectively. Conversely, when
we analyzed serum cardiac troponin and CRP, no
discriminative values were found among patients with or
without follow-up events.
The ROC curves showed that the optimal cut-off
values for serum tryptase in predicting high versus low
MACE rate were ≥ 4.85 ng/ml and ≥ 5.2 ng/ml at T0 and
at T3, respectively.
The correlation between high tryptase levels and the
development of MACE could indicate that the mast cells
have a role in the coronary atherosclerotic damage
process, in which these cells contribute to plaque pro-
gression and destabilization. Bot et al. recently explained
the potential roles of activated mast cells in the growth
and destabilization of an atherosclerotic plaque [13].
Interestingly, one patient with tryptase level of 6.8 ng/ml
experienced a very late stent thrombosis, that developed
18 months after the drug-eluting stent implantation.
In this specific case, we cannot exclude a Kounis syn-
drome variant III, where drug-eluting stent components,including different metal strut, polymers or metal an-
ions, may induce an antigenic complex responsible for a
persistent inflammatory action [14-16]. On the other
hand, as known, mast cells are activated by IgE, but also
by IgE-independent mechanism, cytokines, chemokines,
drugs, physical stimuli and hormones, therefore, these
cells are not only involved in allergic diseases but also in
inflammatory conditions such as atherosclerosis [17] as
well as the chemotaxis of eosinophils and other inflam-
matory cells involved in thrombosis pathogenesis [16].
Atherosclerosis is an inflammatory disease charac-
terized by the progressive accumulation of cholesterol in
the intimal layer of arterial walls leading to the forma-
tion of plaque and vascular obstruction [18]. Mast cells,
like other inflammatory cells, are located in the human
arterial intima and adventitia [19], and when activated,
they release granules locally, which contain a large panel
of mediators, including neutral proteases (tryptase and
chymase), cathepsins, heparin, histamine, cytokines, and
growth factors. During early atherogenesis, the effector
molecules stimulate leukocyte recruitment and lipid
accumulation in the evolving plaque, whereas during
advanced stages of atherogenesis, they contribute to the
generation of an unstable plaque susceptible to rupture
[13]. Tryptase activates metalloproteinases (MMP), such
as MMP-1, MMP-2 and MMP-3 and procollagenase,
and promotes the degradation of lipoproteins and fibro-
nectin [20], acting as powerful inflammatory stimulus at
the endothelial dysfunction [21,22]. Many experimental
studies have confirmed the role of tryptase in the in-
flammatory process of atherosclerosis as well as in aortic
aneurysm formation. Zhang et al. observed a reduction
of abdominal aortic aneurysm formations in tryptase-
deficient mice [23]. Wang et al. recently demonstrated
that the absence, or pharmacological inhibition, of tryp-
tase reduces abdominal aortic aneurysm formation in
animal models [24].
On the basis of these observations, we can suggest that
patients with high serum tryptase levels could have a
greater burden of mast cells in the arterial wall. This
burden contributes to the coronary lesion formation in-
cidence of ACS and the recurrence of follow-up cardio-
vascular events.Conclusions
In conclusion, serum tryptase seems to be a non-invasive,
promising prognostic long-term biomarker in ACS, STEMI
and NSTEMI patients. Higher than 4.85 ng/ml tryptase
levels at the onset of ACS were predictive for occurrence
of MACE within 2 years from the acute event.
Further studies are necessary to define the precise patho-
physiological role of tryptase in cardiovascular diseases and
to confirm its role as prognostic biomarker of ACS.
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